You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
百洋醫藥(301015.SZ)獲安斯泰來三款產品區域內獨家商業化授權
格隆匯 11-09 17:27

格隆匯11月9日丨百洋醫藥(301015.SZ)宣佈,近日,公司與安斯泰來製藥(中國)有限公司(簡稱“安斯泰來”)簽署了《推廣服務協議》,安斯泰來授權百洋醫藥對哈樂、衞喜康、貝坦利三款特定產品規格和包裝規格的產品(簡稱“哈樂合作產品”、“衞喜康合作產品”、“貝坦利合作產品”,或合稱“合作產品”)提供推廣、銷售、宣傳服務(簡稱“推廣服務”)。

該協議自2021年11月9日生效,至2026年8月31日止。如發生協議約定的提前終止情形,協議期限將相應提前到期調整。若無違約情況且未發生終止情形,協議期限自動順延五年至2031年8月31日。

該次簽約後,公司哈樂合作產品授權區域將全面覆蓋各類醫療機構及中國零售市場,衞喜康合作產品、貝坦利合作產品的推廣服務區域包括各類醫療機構及零售市場在內的區域(中國)內全部市場。該次公司與安斯泰來合作,擴大公司哈樂合作產品的授權區域,並新增授權衞喜康、貝坦利兩類合作產品,意味着其對公司品牌運營能力的認可,有助於提高公司品牌影響力,提升公司的市場競爭力。

此外,貝坦利系公司首個國談創新藥產品,該次簽約豐富了公司在泌尿領域的品牌矩陣,進一步加深了雙方在原研藥與創新藥商業化的合作,後續如在授權區域商業化成功,將對公司業績產生積極影響,提升公司持續盈利能力。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account